Oruka Therapeutics, Inc. (NASDAQ: ORKA) saw a notable insider transaction on March 16, 2026 when Chief Medical Officer Joana Goncalves sold a total of 7,641 shares of common stock for an aggregate value of approximately $312,559. The disposition was executed under a pre-established 10b5-1 trading arrangement and consisted of multiple trades at per-share prices spanning $40.1091 to $41.9361, which together accounted for $286,086 of the proceeds.
In addition to those controlled sales, Goncalves sold 641 shares at $41.30 per share, yielding $26,473. That tranche was designated to satisfy tax withholding obligations tied to the vesting of restricted stock units.
Option exercises and resulting holdings
On the same date, Goncalves exercised stock options to acquire 7,000 shares of Oruka common stock. The exercise comprised two equal tranches of 3,500 shares each: one at an exercise price of $6.84 per share and the other at $7.80 per share. The total cash value associated with those option exercises was $51,240.
After completing the sales and option exercises, Goncalves directly holds 33,377 shares of Oruka Therapeutics common stock.
Share-price context and valuation notes
The insider activity occurred while Oruka shares were trading close to a 52-week high of $42.41, following a 251% increase over the prior 12 months. An InvestingPro analysis included with available data characterizes the stock as appearing overvalued at present levels. The same analysis highlights Oruka's balance-sheet position, noting the company has more cash than debt and reports a strong current ratio of 22.37. InvestingPro also indicates that additional proprietary tips and financial metrics are accessible via its platform.
Clinical developments and analyst responses
Oruka has recently disclosed clinical updates that have drawn attention from the investment community. Interim Phase 1 data for ORKA-002 were reported as showing a substantially extended half-life of 75 to 80 days, a property that could permit less frequent dosing if confirmed in later studies for indications such as psoriasis and hidradenitis suppurativa.
Those data points and other timelines prompted multiple analyst actions. Clear Street raised its price target on Oruka to $71 from $46 while maintaining a Buy rating. Stifel lifted its price target to $72 from $47, explicitly citing an accelerated timetable for Phase 2 psoriasis data from ORKA-001, which is now anticipated in the second quarter of 2026. BTIG reiterated a Buy rating and set a price target of $73, noting the earlier-than-expected release of Phase 2a data for ORKA-001. Separately, UBS initiated coverage with a Buy rating and a $50 price target, referencing Oruka's work on a late-stage Phase III selective estrogen receptor degrader - or SERD - for cancer treatment.
Collectively, these developments have generated notable interest among analysts and investors focused on Oruka's clinical programs and potential therapeutic advancements.
What the filings show and what remains to be seen
The filings documenting Goncalves' sale establish the transaction details including the use of a 10b5-1 plan and the tax-related disposition of a portion of shares tied to RSU vesting. The option exercises and post-transaction ownership figures are reflected in disclosure records. Beyond those concrete filings and the company-reported clinical data, future milestones will depend on the progress and timing of ongoing trials and on how subsequent data are received by the market.
Investors and market participants tracking Oruka will likely continue to monitor insider holdings, upcoming clinical readouts for ORKA-001 and ORKA-002, and any further analyst commentary tied to trial results and company fundamentals.